AMENDED AND RESTATED MATERIAL TRANSFER AND RESEARCH AGREEMENTMaterial Transfer and Research Agreement • September 29th, 2023 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Material Transfer and Research Agreement (“Agreement”) is made as of September 20, 2023 (“Effective Date”), by and between AIM IMMUNOTECH, INC., a Delaware Corporation with a principal place of business located at 2117 SW Highway 484, Ocala, Florida 34473 (“AIM”), and Roswell Park Cancer Institute CORPORATION d/b/a roswell park comprehensive cancer centeR, a New York public benefit corporation with a principal place of business located at Elm and Carlton Streets, Buffalo, NY 14263 (“Institute”). AIM and Institute shall be referred to individually as a “party” and together as the “parties.”
